19643 Investors following Dr Reddys Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Dr Reddy's gets USFDA nod for Ondansetron
Dr Reddy's Laboratories Ltd today got the final approval for Ondansetron Hydrochloride, the generic equivalent of the blockbuster drug `Zofran', from the US Food and Drug Administration (USFDA), as well as a 6-month marketing exclusivity.
The company's Ondansetron Hydrochloride tablets are the AB-rated generic equivalent of GlaxoSmithKline's `Zofran' tablets, a product indicated for the prevention of nausea and vomiting associated with cancer treatment.
The brand product has annual IMS sales of approximately $639 million. Today's approval follows an order by the US Court of Appeals for the DC Circuit denying Apotexs request that the FDA not approve the company's generic Zofran products pending a determination of its motion for a preliminary injunction.
Dr Reddy's will commence the shipment of this product shortly. Mr G.V. Prasad, Vice-Chairman and CEO of the company, said, "We are pleased with the final approval of our generic version of Zofran with 180-days of marketing exclusivity. With six product introductions to date in the current year, we are making good progress in building a sustainable base in generics business with potential upsides in the US in the medium term. This reaffirms our commitment to developing one of the largest pipelines in the US generic industry."
